Pancragen (Pancragen (Lys-Glu-Asp-Trp Pancreas Bioregulator))
A short synthetic peptide bioregulator from the Khavinson family targeted at pancreatic tissue. Used in the bioregulator community to support pancreatic function and glucose/metabolic regulation in short repeated courses.
How it works
As a signal peptide (Lys-Glu-Asp-Trp), it is proposed to regulate gene expression in pancreatic tissue, supporting normal endocrine and exocrine pancreatic function and carbohydrate metabolism.
Key facts
- Molecular weight: ~575 Da
- Half-life: Short (peptide)
- Bioavailability: Oral (encapsulated) or subcutaneous
- Storage: Room temperature (capsules) or refrigerate (injectable).
Dosing overview
- Typical dose: ~1-2 capsules/day or short injectable courses
- Frequency: Once daily
- Duration: 10-30 day courses
- Route: Oral capsule or subcutaneous
Protocol notes
- Taken as short repeatable courses (often 10-30 days), a few times per year.
- Oral encapsulated forms are taken once daily on an empty stomach.
- Often used alongside metabolic-support compounds.
Reported benefits
- Pancreatic tissue support
- Carbohydrate metabolism support (proposed)
- Metabolic resilience
- Short course-based protocol
Possible side effects
- Limited Western clinical data
- Injection site reactions (injectable)
- Unknown long-term effects
Research
- Pancreatic peptide bioregulators (2015): Reported to support pancreatic tissue function and carbohydrate metabolism in regional research studies.
Compare Pancragen
Research and educational reference only. Not medical advice.